Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, murine monoclonal antibodies may induce immunogenic responses, potentially limiting their application for humans. Humanized antibodies can overcome these problems and are considered to be a promising alternative therapeutic agent.
BioIntron can provide antibody humanization service based on the CDR grafting and back mutation platform.